L-Lysine,N6-[2-(1H-imidazol-5-yl)ethyl]- (89238-78-8)

Identification
Name:	L-Lysine,N6-[2-(1H-imidazol-5-yl)ethyl]-
Synonyms:	L-Lysine,N6-[2-(1H-imidazol-4-yl)ethyl]- (9CI); (+)-Gizzerosine; (S)-Gizzerosine;Gizzerosine
CAS:	89238-78-8
Molecular Formula:	C11H20 N4 O2
Molecular Weight:	0
InChI:	InChI=1/C11H20N4O2/c12-10(11(16)17)3-1-2-5-13-6-4-9-7-14-8-15-9/h7-8,10,13H,1-6,12H2,(H,14,15)(H,16,17)/t10-/m1/s1
Molecular Structure:
Properties
Flash Point:	270°C
Boiling Point:	522.8°C at 760 mmHg
Density:	1.199g/cm³
Refractive index:	1.559
Flash Point:	270°C
Safety Data

Other Product

L-Lysine,N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-,hydrazide
L-Lysine,N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-,hydrochloride (9CI)
L-Lysine,N6-[2-(1H-indol-3-yl)acetyl]-
L-Lysine,N2-[(1,1-dimethylethoxy)carbonyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
Glucagon (swine),N-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-12-[N6-(1-iminoethyl)-L-lysine]-,monohydrochloride, [3aS-(3aa,4b,6aa)]- (9CI)
Vasopressin,1-(3-mercaptopropanoicacid)-8-[N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-L-lysine]-,[3aS-(3aa,4b,6aa)]- (9CI)
Neuropeptide Y (swine),7-[N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-L-lysine]-,[3aS-(3aa,4b,6aa)]- (9CI)
Substance P,3-[N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-L-lysine]-,[3aS-(3aa,4b,6aa)]- (9CI)
L-Lysine,N6-[6-[[5-[(3aS,4S,6aR)-hexahydro- 2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1- oxopentyl]amino]-1-oxohexyl]-
L-Lysine,N2-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
L-Lysine,N2-[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
L-Lysine,N6-(2-iodoacetyl)-
L-Lysine,N6-(2-pyridinylcarbonyl)-
w-Conotoxin G VIA,2-[N6-[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-1-oxohexyl]-L-lysine]-,[3aS-(3aa,4b,6aa)]- (9CI)
L-Lysine,N2,N2-bis(carboxymethyl)-N6-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]-,potassium salt (1:3)
L-Lysine,1,1'-[[(carboxymethyl)imino]di-2,1-ethanediyl]bis[N-(carboxymethyl)glycyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-(9CI)
D-Lysine,N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-
L-Lysine,N2-[[4,5-dihydro-2-(2-hydroxyphenyl)- 4-oxazolyl]carbonyl]-N6-hydroxy-N6- (1-oxo-2-eicosenyl)-,1-ethyl-3-[(hexahydro- 1-hydroxy-2-oxo-1H-azepin-3-yl)amino]-2- methyl-3-oxopropyl ester,stereoisomer
8-37-Glucagon-like peptide I (human),N-[3-(1H-imidazol-4-yl)-1- oxopropyl]-26-L-arginine-34-[N6-(1- oxooctyl)-L-lysine]-
L-Lysine,N6,N6-dimethyl-